American Society of Hirudotherapy

Raynaud's Syndrome (Primary)

Investigational use for primary Raynaud's phenomenon; the only clinical report is three patients in a 2025 Azerbaijani case series, with no controlled trial.

Tier C — InvestigationalInvestigational: Limited human evidence exists (small trials, case series, or pilot studies). Use is investigational and should be considered carefully under clinician guidance.Last Updated: November 10, 2026 · ASH Editorial · based on the books

Patient Summary

Is this FDA-cleared for this use?
Not FDA-cleared for Raynaud's syndrome. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, 2004). Use for primary Raynaud's is investigational.
What evidence exists?
Only a three-patient report within a 2025 Azerbaijani case series (Farzali et al.) was identified for this condition. Tier C (investigational). There are no randomized controlled trials. Secondary Raynaud's (scleroderma, lupus, antiphospholipid syndrome) requires rheumatology workup. Evidence-based first-line care for primary Raynaud's is conservative measures (warmth, trigger avoidance, smoking cessation) and calcium-channel blockers (nifedipine, amlodipine).
Main risks
  • Bleeding from bite sites for 6 to 24 hours after detachment
  • Bruising and tenderness on the dorsum of the hands for 5 to 10 days
  • Itching and irritation at bite sites
  • Local skin infection or, rarely, Aeromonas infection (especially concerning in patients with compromised distal circulation)
  • Allergic reaction to leech saliva (uncommon)
  • Potential digital ulceration or impaired healing if applied to ischemic fingers
  • Small bite marks that usually fade over weeks to months (rarely a pale spot stays longer)
Who should not consider this
  • Patients on blood thinners (anticoagulants such as warfarin, DOACs or heparin)
  • Patients with hemophilia or other bleeding disorders
  • Patients with anemia
  • Patients with secondary Raynaud's and active vasculitis or critical digital ischemia
  • Patients with active digital ulceration
  • Patients with scleroderma until evaluated and treated by rheumatology
  • Patients with a weakened immune system
What to ask your clinician
  • Have I been evaluated for secondary causes (scleroderma, lupus, antiphospholipid syndrome)?
  • Have I tried trigger avoidance, warmth strategies, smoking cessation, and calcium-channel blockers?
  • What evidence supports leech therapy for Raynaud's specifically?
  • How will distal circulation and skin integrity be assessed before placement?
  • What is the practitioner's experience and Aeromonas-prevention plan?
  • What is the realistic chance of benefit, and for how long?
  • What is the cost, and what does it commit me to?
When to seek urgent care
  • Persistent digital pallor or cyanosis lasting hours, especially with pain
  • New digital ulcers or skin breakdown that won't heal
  • Bleeding from bite sites lasting more than 24 to 48 hours
  • Spreading redness, warmth, pus, or red streaks (cellulitis)
  • Fever above 38.0 C / 100.4 F or chills
  • Hives, throat tightness, or breathing difficulty

What this does NOT mean

  • This is not FDA-cleared for Raynaud's syndrome.
  • Case reports are not evidence of efficacy in the general population.
  • Mechanism rationale (local vasodilation, rheologic improvement) does NOT establish clinical efficacy.
  • Leech therapy does not address secondary Raynaud's underlying disease (scleroderma, lupus).
  • Leech therapy is not a substitute for conservative measures and calcium-channel blockers.

Clinical Profile

Category
Vascular
ICD-10
I73.00, I73.01
Safety tier
Medium

Evidence Summary

The only clinical report identified for leech therapy in Raynaud's phenomenon is a 2025 single-centre Azerbaijan case series of 181 patients across 11 conditions (Farzali et al., Turkiye Parazitol Derg), which included only 3 patients with Raynaud disease; all three were rated a 'success' by examination, patient feedback and physician evaluation, with no validated Raynaud outcome measure and no control group, far too little to establish efficacy. The proposed mechanism involves local vasodilation from salivary vasoactive peptides plus systemic rheologic improvement from absorbed hirudin, but no controlled trials exist. Secondary Raynaud's (associated with scleroderma, lupus, and similar conditions) should be evaluated separately, as treatment of the underlying disease is primary. ASH position: not first-line and investigational; first-line is conservative measures (warmth, avoiding triggers) followed by calcium-channel blockers.

Treatment specifics

How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: where the society's reference books describe a protocol, it is shown in the clinician view — switch the audience selector in the top bar to “Clinician”.)

Contraindications

  • Hemophilia or another bleeding disorder
  • Taking anticoagulants (blood thinners such as warfarin or heparin)
  • Anemia or suppressed blood formation
  • Low blood pressure, shock, collapse or fainting
  • Severe wasting (cachexia)
  • Intolerance of leeches or a history of severe allergic reactions
  • Pregnancy
  • Stomach or duodenal ulcer, erosive gastritis
  • Acute infectious disease or high fever
  • Severe unstable illness, markedly weakened immunity (for example during chemotherapy) or HIV infection
  • Drinking alcohol at the time of treatment
  • No consent from the patient
  • Critical limb ischemia
  • Active digital ulceration or gangrene
  • Secondary Raynaud's with active vasculitis

Related ASH Compounds

Leech molecules and hirudin-derived drugs mentioned for this condition, each profiled in the ASH compound registry:

Related Conditions

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.